|
|
|
||||||||||||
|
|
|
NEWS & EVENTS: Press Releases
November 7, 2011
Promedior Presents Preclinical Data at AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis and Has a Clear Hepatoprotective Effect
November 2, 2011
Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis
May 5, 2011
Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011
February 10, 2011
Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Pulmonary Fibrosis
February 10, 2011
Promedior Initiates Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in Patients with Idiopathic Pulmonary Fibrosis (IPF)
September 7, 2010
Promedior Announces Publication of New Research Demonstrating
Pentraxin-2/SAP is a Potent Inhibitor of Asthma and Asthma-Induced Lung Fibrosis
September 7, 2010
Promedior Announces Initiation of Phase 2a Clinical Study of
Anti-Fibrotic Therapeutic, PRM-151, in the Prevention of Post-Surgical Scarring
in Glaucoma Patients
March 16, 2010
Promedior Closes $12 Million Series
C Financing
November 4, 2009
Preclinical Studies Published in
Science Translational Medicine Demonstrate that Therapeutic Administration of
hSAP Inhibits Fibrosis
October 29, 2009
European Commission Grants
Promedior’s PRM-151 Orphan Drug Designation for the Prevention of Scarring Post
Glaucoma Filtration Surgery
January 22, 2009
Promedior’s Fibrosis Program
Featured at Keystone Symposia Conference
[ back to top ]
|
|
|
|
Fibrosis is the common pathway in virtually all forms of chronic organ failure, including kidney, liver, lung and heart failure. Fibrotic organ failure affects more than 20 million people in the US alone. |
|
|
|
|
|
|
|
|
|